Onkologie. 2021:15(2):63-66 | DOI: 10.36290/xon.2021.012

Total laryngectomy or larynx-preservation strategy? Current treatment approaches

Milan Vošmik1, Jan Klozar2
1 Klinika onkologie a radioterapie LF UK a FN v Hradci Králové
2 Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN Motol, Praha

Patients with resectable laryngeal cancer can be treated with larynx-preservation strategy or total laryngectomy. Larynx-preservation strategy is a standard of care in early stages and involves a larynx-sparing surgery (endoscopic treatment or partial laryngectomy) which is a preferred option, or radiotherapy. In locoregionally advanced stages, non-surgical strategy based on combination of radiotherapy and chemotherapy, or total laryngectomy + postoperative radiotherapy or radiochemotherapy is generally considered. The usual approach in the past, indication for concomitant radiochemotherapy in all locoregionally advanced stages, is currently withdrawn and all treatment options and are considered individually within the multidisciplinary team based on disease parameters, pre-treatment larynx function, patient factors (performance status, age, comorbidities etc.) and patient's preferences.

Keywords: laryngeal cancer, total laryngectomy, partial laryngectomy, larynx-preservation approaches, radiotherapy, radiochemotherapy.

Published: April 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vošmik M, Klozar J. Total laryngectomy or larynx-preservation strategy? Current treatment approaches. Onkologie. 2021;15(2):63-66. doi: 10.36290/xon.2021.012.
Download citation

References

  1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2021-1-03]. Dostupné z: http://www.svod.cz
  2. Succo G, Peretti G, Piazza C, et al. Open partial horizontal laryngectomies: a proposal for classification by the Working Committee on nomenclature of the European Laryngological Society. Eur Arch Otorhinolaryngol. 2014; 271(9): 2489-2496 Go to original source... Go to PubMed...
  3. Machiels JP, René Leemans C, Golusinski W, et al. EHNS Executive Board; ESMO Guidelines Committee. ESTRO Executive Board. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1462-1475. Go to original source... Go to PubMed...
  4. The National Comprehensive Cancer Network. The National Comprehensive Cancer Network Guidelins in Oncology (NCCN Guidelines). Head and Neck Cancers, Version 1.2021 [online]; [cit. 2021-1-03]. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
  5. Mendenhall WM, Mancuso AA, Amdur RJ, et al. Laryngeal cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds.). Perez & Brady's Principles and Practice of Radiation Oncology, 7th edition, Wolters Kluwer 2019:1041-1062.
  6. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; 24(22): 3693-3704. Go to original source... Go to PubMed...
  7. Forastiere AA, Ismaila N, Lewin JS, et al. Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(11): 1143-1169. Go to original source... Go to PubMed...
  8. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324(24): 1685-90. Go to original source... Go to PubMed...
  9. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22): 2091-2098. Go to original source... Go to PubMed...
  10. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival Laryngoscope. 2006; 116 (9 Pt 2 Suppl 111): 1-13. Go to original source... Go to PubMed...
  11. Olsen KD, Reexamining the treatment of advanced laryngeal cancer. Head Neck 2010; 32(1): 1-7. Go to original source... Go to PubMed...
  12. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31(7): 845-852. Go to original source... Go to PubMed...
  13. Ward MC, Adelstein DJ, Bhateja P, et al. Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11. Oral Oncol. 2016; 57: 21-6. Go to original source... Go to PubMed...
  14. Shirasu H, Yokota T, Hamauchi S, et al. Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer. BMC Cancer 2020; 20(1): 182. Go to original source... Go to PubMed...
  15. Chen MC, Kuan FC, Huang SF, et al. Accelerated Risk of Premature Ischemic Stroke in 5-Year Survivors of Nasopharyngeal Carcinoma. Oncologist 2019; 24(9): e891-e897. Go to original source... Go to PubMed...
  16. Vermorken JB, Remenar E, van Herpen C, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17): 1695-1704. Go to original source... Go to PubMed...
  17. Posner MR, Hershock DM, Blajman CR, et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357 (17): 1705-1715. Go to original source... Go to PubMed...
  18. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009; 101(7): 498-506. Go to original source... Go to PubMed...
  19. Janoray G, Pointreau Y, Garaud P, et al. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. J Natl Cancer Inst. 2015; 108(4): djv368. Go to original source... Go to PubMed...
  20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6): 567-578. Go to original source... Go to PubMed...
  21. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013; 31(7): 853-859. Go to original source... Go to PubMed...
  22. Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: Key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009; 73(5): 1293-1303. Go to original source... Go to PubMed...
  23. Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: Issues and outcomes. J Clin Oncol 2015; 33(29): 3262-3268. Go to original source... Go to PubMed...
  24. Hamilton DW, Bins JE, McMeekin P, et al. Quality compared to quantity of life in laryngeal cancer: A time tradeoff study. Head Neck 2016; 38(Suppl 1): E631-637. Go to original source... Go to PubMed...
  25. Dietz A, Wichmann G, Kuhnt T, et al. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. Ann Oncol. 2018; 29(10): 2105-2114. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.